DDInter125 DDInter1000
Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.
Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023.
Asenapine {u} (Compound) resembles {v} (Compound) Amoxapine
Amoxapine {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Asenapine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} (Compound) resembles {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Asenapine {u} (Compound) resembles {v} (Compound) Amoxapine
Amoxapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivosidenib
Asenapine {u} (Compound) binds {v} (Gene) HRH2
HRH2 {u} (Gene) is bound by {v} (Compound) Olanzapine
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Asenapine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loperamide
Loperamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Asenapine {u} (Compound) binds {v} (Gene) HRH1
HRH1 {u} (Gene) is bound by {v} (Compound) Haloperidol
Haloperidol {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Asenapine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} (Compound) resembles {v} (Compound) Olanzapine
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Asenapine {u} (Compound) resembles {v} (Compound) Amoxapine
Amoxapine {u} (Compound) resembles {v} (Compound) Olanzapine
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Asenapine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivosidenib
Asenapine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxepin
Doxepin {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Asenapine (Compound) resembles Amoxapine (Compound) and Amoxapine may lead to a major life threatening interaction when taken with Ivosidenib
Asenapine (Compound) resembles Loxapine (Compound) and Loxapine (Compound) resembles Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Ivosidenib
Asenapine (Compound) resembles Amoxapine (Compound) and Amoxapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Asenapine (Compound) binds HRH2 (Gene) and HRH2 (Gene) is bound by Olanzapine (Compound) and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Asenapine (Compound) resembles Loxapine (Compound) and Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Asenapine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Haloperidol (Compound) and Haloperidol may lead to a major life threatening interaction when taken with Ivosidenib
Asenapine (Compound) resembles Loxapine (Compound) and Loxapine (Compound) resembles Olanzapine (Compound) and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Asenapine (Compound) resembles Amoxapine (Compound) and Amoxapine (Compound) resembles Olanzapine (Compound) and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Asenapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Asenapine (Compound) resembles Loxapine (Compound) and Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Ivosidenib